Analyst Sees Around 1,500% Upside For This Penny Stock Focused On Cancer
Portfolio Pulse from Vandana Singh
EF Hutton has assumed coverage of Sonnet BioTherapeutics Holdings Inc (NASDAQ:SONN) with a Buy rating and a $6.70 price target. Sonnet's lead clinical candidate, SON-1010, is designed to maximize the benefits of cytokines against solid tumors. The company is now enrolling the final dose cohort in the cancer trial.
May 25, 2023 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sonnet BioTherapeutics receives a Buy rating and $6.70 price target from EF Hutton. The company's lead clinical candidate, SON-1010, is progressing in cancer trials.
The Buy rating and $6.70 price target from EF Hutton indicate a positive outlook for Sonnet BioTherapeutics. The company's lead clinical candidate, SON-1010, is designed to maximize the benefits of cytokines against solid tumors, and the ongoing cancer trial enrollment shows progress in their research. This news is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100